Bigbear Pharmaceutical·Medication Guide

• What is acalabrutinib used for

  Acalabrutinib is used for adult patients with:chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL) patientswho···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 75

• How does acalabrutinib work

  Cancer cells get signals to grow and divide from a protein called Bruton tyrosine kinase (BTK). Acalabrutinib mechanism of action is by blocking BTK t···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 75

• FDA Approves Calquence (acalabrutinib) for Adults with Mantle Cell Lymphoma

  October 31, 2017 -- The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults ···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 72

• FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia

  21 November 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patien···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 73

• Calquence Plus Chemoimmunotherapy Approved in the U.S. for Patients with Previously Untreated Mantle

  17 January 2025 -- AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatmen···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 72

• Calquence Tablet Formulation Approved in the US Across Current indications

  Key Advantages of the New Tablet Formulation- New formulation can be co-administered with gastric acid-reducing agents- Tablet offers equivalent effic···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 72

• Calquence Plus Venetoclax Approved in the US as First All-Oral, Fixed-Duration Combination for Patie

  20 February 2026 -- AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-du···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 72

• What Happens if I Take/Give Too Much Rinvoq/Rinvoq LQ

  If you take too much Rinvoq/Rinvoq LQ, call your healthcare provider or Poison Help line at 1-800-222-1222, or go to the nearest hospital emergency ro···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 75

• Can I drink grapefruit juice with Rinvoq

  No, you shouldavoid foods or drinks that contain grapefruitwhile you are being treated with Rinvoq. Consuming grapefruit or the juice may increase the···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 78

• What is Rinvoq prescribed for

  Rinvoqis available as an extended-release oral tablet or as an oral solution. It is approved to treat:Rheumatoid arthritisPsoriatic arthritisAtopic de···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 77

• How quickly does Rinvoq work

  You may feel the effects of Rinvoq oral tablet after one or two weeks, but most people with rheumatoid arthritis who respond have significant improvem···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 76

• Rinvoq (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Sp

  NORTH CHICAGO, Ill., April 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved ···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 74

• FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rh

  NORTH CHICAGO, Ill., Aug. 16, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 73

• Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely

  NORTH CHICAGO, Ill., March 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved ···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 73

• Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Active Non-Radiographic

  NORTH CHICAGO, Ill., Oct. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announces that the U.S. Food and Drug Administration (FDA) has approved R···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 72